Blood Plasma Market to Reach US$ 54.2 Billion by 2033, Growing at 7.1% CAGR: Persistence Market Research

The global blood plasma market is witnessing substantial growth, driven by rising demand for plasma-derived therapeutics, particularly immunoglobulins and albumin, and advances in plasma collection and fractionation technologies. As the market continues to expand, it is expected to be valued at USD 33.5 billion by 2026 and reach USD 54.2 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.1% between 2026 and 2033. The rising burden of immunodeficiency, autoimmune disorders, and the increasing use of plasma in chronic disease management are the primary drivers of this growth.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/3148

What is Blood Plasma and Its Role in Healthcare?

Blood plasma is the liquid portion of blood that constitutes about 55% of the blood's total volume. Composed of over 700 proteins, plasma plays a vital role in transporting nutrients, hormones, and proteins throughout the body, aiding in the regulation of blood pressure and body temperature. Plasma contains critical proteins such as albumin, clotting factors, and immunoglobulins, which are extracted and used in the development of therapeutic products to treat a range of serious health conditions like hemophilia, autoimmune disorders, and immunodeficiency.

Plasma-derived therapies are particularly essential in the management of rare, chronic diseases, as they provide life-saving treatment options for conditions like immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and various immunodeficiencies. These therapies, such as immunoglobulins and clotting factors, are in high demand and contribute significantly to the market's growth trajectory.

Market Dynamics: Drivers and Restraints

Driver - Rising Burden of Immunodeficiency and Autoimmune Disorders
The increasing prevalence of primary and secondary immunodeficiency disorders is one of the key drivers of the global blood plasma market. Immunoglobulin therapies, including intravenous and subcutaneous forms, are becoming standard treatments for these conditions. The World Health Organization (WHO) recognizes thousands of cases of primary immunodeficiency worldwide, with diagnosis rates rising rapidly in developed regions like North America, Europe, and parts of Asia. The chronic nature of these therapies, which often require lifelong treatment, underpins the growing consumption of plasma-derived products, particularly immunoglobulins. Furthermore, these products are also crucial in treating autoimmune disorders such as chronic inflammatory demyelinating polyneuropathy and immune thrombocytopenia, creating a steady demand for these therapies.

Driver - Expansion of Plasma Collection Infrastructure and Technology
The significant increase in global plasma supply over the past decade has been a critical factor in supporting the growth of the blood plasma market. In the United States, which contributes a large share of plasma for fractionation, there are more than 1,200 active plasma collection centers. Major players such as CSL, Grifols, Takeda (BioLife), and Octapharma have led the expansion, increasing the number of collection centers by more than 50% in recent years. The introduction of next-generation plasmapheresis systems, such as the Rika system deployed at CSL centers, has improved collection efficiency by increasing the yield per session by 10%. These advancements have made plasma collection more cost-effective, helping meet rising clinical demand and boosting revenue growth across therapeutic segments.

Restraint - Supply-Demand Imbalance and Risk of Product Shortages
Despite the expansion of plasma collection infrastructure, the balance between global plasma supply and the demand for plasma-derived medicinal products remains tight. Plasma shortages have been observed periodically in several regions, often triggered by disruptions in donor participation, logistical constraints, or regulatory interventions. Such shortages can lead to treatment delays, forcing clinicians to prioritize critical cases and, at times, switch patients to alternative therapies. This volatility in supply can temper near-term market growth and present challenges for manufacturers trying to meet rising demand for plasma-derived products.

Restraint - Stringent Regulatory Requirements and Manufacturing Complexity
The production of plasma-derived therapies is heavily regulated due to the biological origin of the products. Strict guidelines are enforced by regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) to ensure the safety, traceability, and consistency of these products. Compliance with these regulations requires significant investments in manufacturing facilities, pathogen inactivation processes, and quality control systems, which can increase production costs and limit pricing flexibility. Smaller companies may face barriers to entering the market due to these high entry costs and regulatory hurdles.

Get Custom Insights Designed for Your Businecss: https://www.persistencemarketresearch.com/request-customization/3148

Opportunity - High Growth Potential in Albumin and Emerging Therapeutic Uses
The albumin segment is expected to be one of the fastest-growing plasma types, driven by its expanding use beyond traditional indications such as liver cirrhosis and hypovolemia. Emerging clinical data supports albumin's effectiveness in critical care, fluid resuscitation, sepsis management, and perioperative settings. Additionally, ongoing research is exploring its potential benefits in treating stroke, cardiac surgery recovery, and as a drug delivery agent. The growing demand for albumin in Asia Pacific, particularly in China and India, as healthcare infrastructure improves and intensive care services scale up, presents a significant growth opportunity for manufacturers.

Opportunity - Growing Demand for Plasma-Derived Therapies in Rare and Chronic Disorders
Another lucrative opportunity in the blood plasma market is the increasing demand for plasma-derived therapies for rare and chronic disorders. Conditions like hereditary angioedema, von Willebrand disease, and various coagulation factor deficiencies rely heavily on plasma-derived factor concentrates. These treatments are particularly important in low- and middle-income countries where access to recombinant therapies is limited due to cost. Additionally, the development of hyperimmune globulins targeting specific pathogens or antigens, including those for emerging infectious diseases, opens new therapeutic avenues with potential for premium pricing.

Category-wise Analysis

By Plasma Type
Immunoglobulins currently dominate the blood plasma market, accounting for 47% of global revenues. The broad range of clinical applications, high chronic usage, and proven efficacy in treating immunodeficiency and autoimmune disorders contribute to immunoglobulins' dominant market share. Immunoglobulins are also increasingly used in neurology and hematology, further expanding their demand.

Albumin is also a significant segment within the market, with increasing utilization in critical care settings. The growing demand for albumin in Asia Pacific, driven by improvements in healthcare infrastructure, is expected to propel this segment's growth over the forecast period.

By End-User
Hospitals are the largest end-users of blood plasma products, accounting for approximately 55% of the global market share. Hospitals are the primary sites for the administration of plasma therapies in acute care settings, including major surgeries, trauma cases, liver failure, severe infections, and critical bleeding disorders. The advanced treatment protocols and the need for close patient monitoring contribute to hospitals' dominance in the market. Although outpatient clinics and infusion centers are gradually expanding their role in long-term immunoglobulin maintenance therapy, hospitals are expected to remain the largest end-user segment throughout the forecast period.

Regional Insights

North America
North America, particularly the United States, leads the global blood plasma market, holding a 42% share of global demand. The region's dominance can be attributed to high diagnosis rates, advanced healthcare infrastructure, and a dense network of plasma collection centers. The U.S. has over 1,200 FDA-registered plasma donation centers, with large operators such as CSL, Grifols, and Takeda (BioLife) controlling the majority of these facilities. Strong reimbursement for plasma-derived therapies, coupled with advanced regulatory oversight, supports the robust demand for immunoglobulins and other plasma-derived products in the region.

Asia Pacific
Asia Pacific is poised to become the fastest-growing region for blood plasma, driven by rising healthcare expenditure, an aging population, and increasing awareness of plasma therapies in countries like China, Japan, and India. The expansion of plasma fractionation capacity in China, alongside investments in manufacturing facilities in India and Southeast Asia, is expected to fuel the region's growth. As awareness and reimbursement programs increase, the demand for plasma-derived products, particularly immunoglobulins and albumin, is expected to grow rapidly.

Get Custom Insights Designed for Your Businecss: https://www.persistencemarketresearch.com/request-customization/3148

Global Blood Plasma Market Segmentation

By Plasma Type

Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others

By Application

Hemophilia
Immunodeficiency Diseases
Von Willebrand's Disease
Others

By End-User

Hospitals
Clinics
Others

By Region

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa

Competitive Landscape

The blood plasma market is moderately consolidated, with a few large multinational companies dominating the industry. Leading players include CSL, Grifols, Takeda Pharmaceuticals, Octapharma, and Kedrion, which control a significant share of plasma collection and fractionation capacity. These companies compete on the scale of their plasma networks, product portfolios, safety records, and global distribution capabilities. Strategic initiatives, such as acquisitions of plasma centers and investments in advanced plasmapheresis technologies, are helping these players maintain their market leadership. At the same time, regional players and public blood establishments are focusing on selective product lines and domestic self-sufficiency to capitalize on niche market opportunities.

Key Industry Developments

In May 2025, BIOIIFE, a subsidiary of Takeda, deployed Fresenius Kabi's Adaptive Nomogram technology across U.S. plasma centers using the Aurora Xi Plasmapheresis System. This innovation is expected to increase plasma volumes by 11.5%, improving collection efficiency. In July 2024, Biotest AG partnered with Kedrion to commercialize its immunoglobulin therapy, Yimmugo, in the U.S. following FDA approval.

Conclusion

The global blood plasma market is poised for significant growth over the next decade. With the rising burden of immunodeficiency and autoimmune disorders, along with advancements in plasma collection and fractionation technologies, the market offers lucrative opportunities for established and emerging players. However, challenges related to supply-demand imbalances, regulatory hurdles, and manufacturing complexities must be addressed to sustain this growth.

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.